MRI Drugs Leave Toxic Heavy Metal Residue in the Brain

The AHA! Team — Wed, 27 Aug 2025 05:49:18 +0000

Lori Alton via NaturalHealth365 – MRIs help doctors see inside your body, but new findings have raised red flags. Medical experts want more research on health risks – especially how these metal-based contrast agents might build up in your body long after the scan. Many MRI procedures involve getting a contrast injection to improve the clarity of the images. The problem is that some patients with multiple MRIs report thinking problems afterward. These symptoms increasingly point to gadolinium, a metal used in contrast agents that may be more dangerous than we thought. New research shows it can stay in your body for years, even with healthy kidneys. What’s particularly concerning is that gadolinium might damage your cells and even your DNA. Scientific studies raise serious brain health concerns A study showed a correlation between intravenous gadolinium-based contrast agents and deposits of gadolinium found in neural tissues. Results were published online in Radiology, with lead author Robert McDonald, MD, PhD, Mayo Clinic, noting that some of the administered doses of contrast agent deposited in neural tissues were surprising. Patients who have undergone routine MRIs, such as Marcie Jacobs, later reported a loss of cognitive abilities. After having memory and other brain function issues following several years of routine MRIs for breast cancer detection, Ms. Jacobs ended up on disability. Also in the journal Radiology, Dr. Emanuel Kanal, University of Pittsburgh Medical Center, along with Michael Tweedle at Ohio State University, wrote that current studies “called into question” the “safety of at least some” of the agents. While the two did not call for an end to the use of these agents, they did call for increased caution in using these drugs. Are you being offered these MRI drugs? About a third of all MRIs in America still use gadolinium-based contrast agents, even as questions linger about their long-term safety. The FDA has tightened regulations rather than banning the most problematic agents outright – taking a different approach than European regulators who pulled Omniscan and Magnevist from their markets back in 2018. This safety debate isn’t new. Back in 2007, the U.S. Food and Drug Administration (FDA) first required warnings after research linked certain agents to nephrogenic systemic fibrosis, a serious condition causing tissue hardening, particularly in kidney patients who struggle to clear the metal from their bodies. Despite two FDA reviewers pushing for an outright ban on high-risk agents, the agency opted for stronger warnings instead. By 2010, they recommended against using Omniscan, Magnevist, and Optimark for patients with kidney problems. In 2018, warnings expanded to include gadolinium retention risks even for people with healthy kidneys. These days, doctors typically reach for newer macrocyclic agents, which hold their gadolinium more securely and seem less likely to release it into body tissues. However, the debate continues about whether these regulatory steps go far enough to protect patients. Gadolinium brain deposits spark ongoing safety debate Brain scans after certain contrast-enhanced MRIs show gadolinium sticking around – a discovery that’s raised eyebrows across medicine even without clear proof of harm. The findings haven’t definitively shown these metal deposits cause problems, but they’ve certainly got doctors thinking twice. GE Healthcare insists its research shows no evidence of harm from these brain deposits. Bayer has been working with outside researchers to get to the bottom of things. Both companies have settled their share of lawsuits, including some involving deaths. Back in 2010, Bayer reached a settlement with a California man who claimed Bayer’s product Magnevist gave him nephrogenic systemic fibrosis – a rare but serious condition. The health dangers continue to be a hot topic of debate. Research points in different directions – some studies raise red flags while others find no smoking gun. Doctors now find themselves weighing benefits against possible risks, especially when their patients already have kidney problems. The risk to MRI patients continues Doctors now check kidney function before giving patients contrast agents, but that might not solve the problem. We’re seeing gadolinium deposits showing up even in people with healthy kidneys, sometimes months or years after their MRIs. Researchers are worried about finding these metal traces in brain tissue at much higher levels than anyone thought possible. We don’t know yet how this might affect someone’s brain function or overall health over the long haul. The data simply isn’t there. This puts radiologists in a tough spot. These contrast agents help spot tumors, inflammation, and blood vessel problems that might otherwise go undetected. That’s incredibly valuable – but at what risk? Some hospitals have started switching to newer gadolinium compounds like the macrocyclic agents, which seem to hold onto their gadolinium better than older ones like Omniscan and Magnevist. Others are cutting doses to the bare minimum or skipping contrast altogether when possible. For patients needing multiple MRIs throughout their lives, the risk increases with each scan. Many are now asking for contrast-free procedures or looking for facilities that use the newer, possibly safer agents. Until we know more, the smart move seems to use the least risky contrast agents only when absolutely necessary. Meanwhile, researchers keep studying what happens to these metal deposits in the body over time. One thing’s for sure – we haven’t heard the last word on gadolinium safety. Editor’s note: Find out more about how to keep your kidney health strong, own the Fatty Liver Docu-Class package created by NaturalHealth365 Programs, that includes the Kidney Health Docu-Class. Sources for this article include: NIH.gov FDA.gov FDA.gov Current.com Auntminnie.com Propublica.org To read the original article click here.

The post MRI Drugs Leave Toxic Heavy Metal Residue in the Brain appeared first on Amazing Health Advances.

Reducing Aluminium Intake Can Minimize Potential Health Risks

AHA Publisher — Wed, 15 Jan 2020 08:00:19 +0000

BFR Federal Institute for Risk Assessment via EurekAlert – Consumers can take up aluminium compounds from various sources, such as food, cosmetic products like aluminum containing antiperspirants and toothpaste, food contact materials like uncoated aluminum menu or baking trays and drugs. For the first time, the BfR has now estimated the total aluminum intake for different age groups (infants, children and adolescents as well as adults) and carried out a risk assessment. In addition, the contributions of the various sources of total aluminium intake by the population were compared with one another. A high intake of aluminium compounds can cause, among other things, neurotoxic developmental disorders as well as damage the kidneys, liver and bones. The BfR bases its assessment of the population’s aluminium intake from food on the latest consumption and concentration data. Consumption data are collected through consumer surveys and provide information on which foods and how much of them are eaten by different consumer groups. The concentration data used show the average aluminium concentrations in the different food categories. For non-food products, such as cosmetics or packaging, the exposure assessment is also based on data regarding aluminium contents in the products. Furthermore, typical application forms and quantities are taken into account. For the risk assessment of aluminium intake, the BfR uses the tolerable weekly intake (TWI) derived from the European Food Safety Authority (EFSA) of 1 milligram aluminium per kilogram body weight. The BfR’s assessment shows that aluminium intake from food is lower compared to previous studies. Food is still a relevant, but no longer the population’s main source of intake. If other relevant sources of aluminium intake are taken into account, such as aluminium containing cosmetic products and uncoated food contact materials, the total intake can exhaust or even exceed the TWI for all age groups. Consumers can influence their aluminium intake. Those who want to reduce their aluminium intake should use aluminium containing antiperspirants and toothpaste sparingly. When it comes to food, the BfR recommends a varied diet as well as alternating products and brands. This can contribute to reducing the risk of permanently high aluminium intake caused by individual highly contaminated products. The BfR recommends, also for other reasons, exclusively breastfeeding infants in the first six months of life, if possible. The BfR generally advises against the preparation and storage of, in particular, acidic and salty foods in uncoated aluminium articles or aluminium foil. If the aforementioned and avoidable sources of intake are reduced, most consumers are not expected to suffer any adverse health effects. The BfR recommends that manufacturers take appropriate measures to reduce the amount of aluminium in food. These may include, for example, using raw materials with low aluminium content or coated materials for processing and packaging food. There is still a high level of uncertainty in aluminium risk assessment because important data is still missing or can be interpreted differently. This concerns, for example, the question of how much aluminium is actually absorbed through the skin as well as the possible occurrence of certain long-term consequences of chronic exposure to aluminium. To read the original article click here.

The post Reducing Aluminium Intake Can Minimize Potential Health Risks appeared first on Amazing Health Advances.

toxic metal Archives - Amazing Health Advances

MRI Drugs Leave Toxic Heavy Metal Residue in the Brain

Reducing Aluminium Intake Can Minimize Potential Health Risks